Mulpleo (Lusutrombopag)

Mulpleo is a thrombopoietin receptor agonist that acts on platelet production pathways.

• Thrombocytopenia in chronic liver disease: helps raise platelet counts before invasive procedures.
• Pre‑procedure platelet support: reduces the need for platelet transfusions in at‑risk patients.
• Chronic liver disease management: contributes to overall hematologic stability during treatment.

• Lusutrombopag binds to and activates the thrombopoietin (c‑Mpl) receptor on megakaryocyte precursors, stimulating their proliferation and differentiation. This activation increases platelet production in the bone marrow, thereby raising circulating platelet levels without directly affecting coagulation pathways.

Adverse reactions reported with lusutrombopag are generally mild to moderate.

Common Side Effects

• Headache: mild and transient.
• Nausea: occasional, often resolves without intervention.
• Fatigue: low‑grade tiredness reported by some patients.
• Diarrhea: mild gastrointestinal upset.
• Elevated liver enzymes: transient increase in hepatic transaminases.

Serious or Rare Side Effects

• Thromboembolic events: rare but potentially serious clot formation.
• Severe hypersensitivity: rash, itching, or swelling requiring medical attention.
• Hepatic decompensation: worsening liver function in susceptible individuals.
• Severe thrombocytosis: excessively high platelet counts.
• Immune‑mediated platelet destruction: rare autoimmune reaction.
• Unexplained bleeding: despite platelet rise, rare bleeding episodes may occur.

Mulpleo should be used under careful medical supervision, especially in patients with liver impairment.

• Baseline platelet count: obtain before initiating therapy.
• Liver function monitoring: assess enzymes periodically.
• Concomitant anticoagulants: evaluate bleeding risk when used together.
• Pregnancy and lactation: avoid unless benefits outweigh risks.
• Renal impairment: adjust use based on clinical judgment.
• Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Lusutrombopag may interact with several drug classes, requiring attention to dosing and monitoring.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors: may increase lusutrombopag exposure.
• Anticoagulants (e.g., warfarin): heightened risk of bleeding.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers: may reduce drug effectiveness.
• Other thrombopoietin receptor agonists: additive platelet‑raising effect.
• NSAIDs: potential for gastrointestinal irritation.
• Herbal supplements affecting liver enzymes: monitor liver function tests.